Research programme: tubulin polymerisation inhibitors - SALVATAlternative Names: SVT 4703; SVT004703
Latest Information Update: 31 May 2010
At a glance
- Originator SALVAT
- Class Imidazoles
- Mechanism of Action Tubulin polymerisation inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 06 Dec 2006 Preclinical trials in Cancer in Spain (unspecified route)